Pancreatic Cancer Research

ResearcherUniversity Hospitals Birmingham NHS Foundation TrustActive in the last 2 years

David Christopher Bartlett

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8564-9420; OpenAlex author ID A5101747116, A5139026321. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2022: 2 papers · 2023: 2 papers · 2024: 3 papers · 2025: none · 2026: 7 papers

Papers 14

  1. Colonization of bile with gammaproteobacteria is associated with reduced survival after surgery for pancreatic cancer in patients receiving gemcitabine-based a… Co-author DOI 10.1016/j.ejso.2026.111396↗
  2. Effect of duration of neoadjuvant therapy on pancreatic cancer outcomes: a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2025.12.018↗
  3. Intention to treat outcomes following management of locally advanced pancreatic ductal adenocarcinoma with curative intent: single centre cohort study. Co-author DOI 10.1016/j.hpb.2026.06.008↗
  4. Temporary Mesocaval Shunt: A Surgical Strategy to Facilitate Pancreatic Cancer Resection With Complex Vascular Involvement. Co-author DOI 10.1111/ans.70977↗
  5. Neoadjuvant Chemoradiotherapy Versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis of Randomised Contro… Co-author DOI 10.1245/s10434-026-20319-7↗
  6. ASO Author Reflections: It is Time to Define an Optimal Duration of Neoadjuvant Treatment in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20436-3↗
  7. ASO Visual Abstract: Neoadjuvant Chemoradiotherapy versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis… Co-author DOI 10.1245/s10434-026-20533-3↗
  8. Can preoperative Carbohydrate Antigen 19-9 predict metastatic pancreatic cancer? Results of a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2024.01.017↗
  9. Meta-analysis of survival after pulmonary resection for isolated metachronous pancreatic cancer metastasis: a promising, albeit infrequent, approach. Last author DOI 10.1016/j.hpb.2024.05.015↗
  10. Staging Computed Tomography Parameters Predict the Need for Vein Resection during Pancreaticoduodenectomy in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diagnostics14020135↗
  11. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  12. Vein Wall Invasion Is a More Reliable Predictor of Oncological Outcomes than Vein-Related Margins after Pancreaticoduodenectomy for Early Stages of Pancreatic … Co-author DOI 10.3390/diagnostics13223465↗
  13. Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-… Co-author DOI 10.1136/bmjopen-2021-050166↗
  14. Para-aortic lymph node involvement should not be a contraindication to resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v14.i5.429↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert Peter Sutcliffe · 12 shared papers, 2022–2026 · strength 2.90
  2. Nikolaos A. Chatzizacharias · 11 shared papers, 2022–2026 · strength 2.59
  3. Keith John Roberts · 10 shared papers, 2022–2026 · strength 2.42
  4. S.S. Raza · 9 shared papers, 2024–2026 · strength 2.29
  5. Shahin Hajibandeh · 6 shared papers, 2024–2026 · strength 1.67
  6. Shahab Hajibandeh · 6 shared papers, 2024–2026 · strength 1.67
  7. Rupaly Pandé · 3 shared papers, 2022–2024 · strength 0.50
  8. Lewis A Hall · 2 shared papers, 2026 · strength 0.46
  9. Peter Lawrence Zaki Labib · 2 shared papers, 2026 · strength 0.46
  10. Sarah F. Powell-Brett · 2 shared papers, 2026 · strength 0.46
  11. Moath Alarabiyat · 2 shared papers, 2026 · strength 0.46
  12. Manish Singh Ahuja · 2 shared papers, 2022–2023 · strength 0.31
  13. Charlotte Terry · 1 shared paper, 2026 · strength 0.28
  14. Nabeel Merali · 1 shared paper, 2026 · strength 0.28
  15. Adam Enver Frampton · 1 shared paper, 2026 · strength 0.28
  16. Shivan Sivakumar · 1 shared paper, 2026 · strength 0.18
  17. Nicola de Liguori Carino · 1 shared paper, 2022 · strength 0.13
  18. Kurinchi Selvan Gurusamy · 1 shared paper, 2022 · strength 0.13
  19. Paula Ghaneh · 1 shared paper, 2022 · strength 0.13
  20. Daniel H. Palmer · 1 shared paper, 2022 · strength 0.13
  21. Zainab L. Rai · 1 shared paper, 2022 · strength 0.13
  22. Brian Ritchie Davidson · 1 shared paper, 2022 · strength 0.13
  23. Derek Manas · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.